-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 20, Hanson Pharmaceuticals announced that the marketing license application for the company's innovative drug deuterosoxitinib tablets has been accepted by the State Drug Administration for adult patients with moderate to severe plaque psoriasis. This is the first domestically produced TYK2 allosteric inhibitor approved by NDA.
Share
Listen to the news
On November 20, Hanson Pharmaceuticals announced that the marketing license application for the company's innovative drug deuterosoxitinib tablets has been accepted by the State Drug Administration for adult patients with moderate to severe plaque psoriasis. This is the first domestically produced TYK2 allosteric inhibitor approved by NDA.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending